Anvisa suspends advertising of weight loss pen
Graduated in journalism from Paulista University. Worked in media outlets such as Folha de S.Paulo and Rede Brasil de Televisão. Is an Oeste reporter in São Paulo
TL;DR
- Anvisa suspended advertising for the medication Semavy, which contains semaglutide.
- The drug is used for type 2 diabetes and weight control.
- Advertising was suspended because it targeted the general public, violating Brazilian law.
- The suspension affects advertisements on electronic billboards, websites, and social media.
- The drug's registration, sale, and use are not affected by the decision.
- Hypera Pharma's subsidiary, Cosmed, is responsible for Semavy and stated they are adapting their communications according to Anvisa's directives.